Results 141 to 150 of about 326,443 (336)

Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+ISH+ and HER2 3+ in HER2-Positive Breast Cancer

Cancer Research and Treatment
Dual anti-HER2 drugs has become the standard regimen for neoadjuvant systematic treatment (NST) to HER2-positive breast cancer patients. However, the efficacy varies greatly among patients with different HER2 protein expression levels.A total of 575 HER2-positive breast cancer patients from multiple centers throughout China from 2013 to 2022 were ...
Lingjun, Ma, Ran, Zheng, Lingyun, Xu, Ying, Zhu, Hong, Yin, Xiaoqing, Zhang, Rong, Deng, Jue, Wang, Xiaoming, Zha   +8 more
openaire   +2 more sources

Implications of HER2 Status on Local Control and Adverse Radiation Effects After Stereotactic Radiosurgery for Brain Metastases of Breast Cancer [PDF]

, 2017
Jason W. Chan, Yao Yu, Steve Braunstein, Jean L. Nakamura, Shannon Fogh, Lijun Ma, Philip V. Theodosopoulos, Michael W. McDermott, Penny K. Sneed   +8 more
openalex   +1 more source

GlycoChat Uncovers Glycan–Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer

Advanced Science, EarlyView.
Aberrant glycosylation drives cancer progression, yet its role in the tumor microenvironment remains unclear. We developed GlycoChat to map glycan–lectin circuits at single‐cell resolution. We discovered that cancer cells induce immunosuppressive macrophage differentiation and impair phagocytosis through interactions with CLEC10A and SIGLEC3 ...
Dinh Xuan Tuan Anh, Sunanda Keisham, Arun Burramsetty, Lalhaba Oinam, Koichiro Kumano, Akihiro Kuno, Osamu Shimomura, Tatsuya Oda, Hiroaki Tateno   +8 more
wiley   +1 more source

Novel sulfonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers

Journal of Enzyme Inhibition and Medicinal Chemistry, 2019
A series of sulfonamide benzoquinazolinones 5–18 was synthesized and evaluated for cytotoxic activity against MDA-MB-231 cell line. The compounds showed IC50 ranging from 0.26 to 161.49 µM.
Aiten M. Soliman, Ali S. Alqahtani, Mostafa M. Ghorab   +2 more
doaj   +1 more source

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

Advanced Science, EarlyView.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang, Jiangang Xu, Xinyu Zhou, Lu Che, Minghan Qiu, Yang Liu, Ming Gao, Zhen Yang   +7 more
wiley   +1 more source

NIR Ratiometric Fluorescent Antibody‐Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring

Advanced Science, EarlyView.
In vivo optical imaging enhances antibody‐drug conjugate (ADC) optimization by enabling real‐time monitoring of stimulus‐responsive drug behavior. We report n501‐CYMMAF, a ratiometric theranostic with strong target affinity and low‐dose efficacy for ovarian metastasis.
Cheng Li, Zezhong Yu, Tao Pu, Yanling Wu, Gang Wang, Youhua Xie, Tianlei Ying, Zhenlin Yang, Yibing Shi   +8 more
wiley   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source

Targeting IL27RA Enhances Immunotherapy in Triple‐Negative Breast Cancer by Modulating Tumor Cells and the Tumor Microenvironment

Advanced Science, EarlyView.
IL27RA upregulation drives immune evasion in TNBC by suppressing MHC‐I expression and reprogramming T/NK‐cell states, establishing an immune‐excluded tumor phenotype. Targeting this epithelial‐intrinsic IL27RA–PI3K/AKT axis offers a promising strategy to overcome immunotherapy resistance.
Jiachi Xu, Qian Long, Meirong Zhou, Qitong Chen, Jing Peng, Qingchun Liang, Danhua Zhang, Hui Zhou, Wenjun Yi   +8 more
wiley   +1 more source

Protons Show Greater Relative Biological Effectiveness for Mammary Tumorigenesis with Higher ERα- and HER2-Positive Tumors Relative to γ-rays in APCMin/+ Mice

, 2020
Shubhankar Suman, Igor Shuryak, Bhaskar Kallakury, David J. Brenner, Albert J. Fornace, Michael D. Johnson, Kamal Datta   +6 more
openalex   +2 more sources

Core Fucosylation Represses SMURF1‐Dependent Degradation of CD47 to Promote Tumor Immune Evasion

Advanced Science, EarlyView.
FUT8‐mediated core fucosylation of CD47 at N111 blocks SMURF1 binding and reduces CD47 ubiquitination and degradation. Blocking N111 glycosylation reduces CD47 expression and promotes macrophage phagocytosis of tumor cells. Furthermore, ablating CD47 core fucosylation boosts CD103+ dendritic cells (DCs) infiltration, increases natural killer (NK) cell ...
Yuting Cao, Siyuan Chai, Mingyang Li, Xiaoming Chen, Jiating Hu, Bingyi Lin, Liming Wu, Wen Yi, Qiang Zhu   +8 more
wiley   +1 more source